Whole Blood Transcriptional and Mass Cytometry Immune Profiling in Systemic Lupus Erythematosus (SLE) Patients to Discern the Salutary Effects of Belimumab on Halting Disease Progression and Flares Without Compromising Host Fitness
Latest Information Update: 13 Jun 2024
At a glance
- Drugs Belimumab (Primary) ; Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- 08 Jun 2024 Status changed from not yet recruiting to completed.
- 04 Dec 2020 Planned End Date changed from 30 Sep 2023 to 30 Dec 2023.
- 04 Dec 2020 Planned primary completion date changed from 30 Sep 2023 to 30 Dec 2023.